Low molecular weight heparin stimulates megakaryocytopoiesis in bone-marrow transplantation patients

R Or; S Elad; O Shpilberg; A Eldor

doi:10.1002/(SICI)1096-8652(199609)53:1<46::AID-AJH11>3.0.CO;2-1

Low molecular weight heparin stimulates megakaryocytopoiesis in bone-marrow transplantation patients

Am J Hematol. 1996 Sep;53(1):46-8. doi: 10.1002/(SICI)1096-8652(199609)53:1<46::AID-AJH11>3.0.CO;2-1.

Authors

R Or¹, S Elad, O Shpilberg, A Eldor

Affiliation

¹ Department of Bone Marrow Transplantation, Hadassah University Hospital, Jerusalem, Israel.

PMID: 8813098
DOI: 10.1002/(SICI)1096-8652(199609)53:1<46::AID-AJH11>3.0.CO;2-1

Abstract

The use of low molecular weight heparin (LMWH) as prophylaxis for veno-occlusive disease of the liver has been studied in patients undergoing bone marrow transplantation (BMT). The present study analyzes the effect of LMWH on the time course of platelet recovery after BMT. Significantly accelerated platelet recovery in conjunction with lessened requirements of platelet transfusions was observed in the LMWH-treated patients.

Publication types

Clinical Trial
Randomized Controlled Trial

MeSH terms

Anticoagulants / pharmacology*
Anticoagulants / therapeutic use
Biological Availability
Blood Platelet Disorders / etiology
Blood Platelet Disorders / physiopathology
Blood Platelet Disorders / prevention & control*
Bone Marrow Transplantation / adverse effects
Bone Marrow Transplantation / physiology*
Enoxaparin / pharmacology*
Enoxaparin / therapeutic use
Feasibility Studies
Half-Life
Humans
Injections, Subcutaneous
Megakaryocytes / drug effects*
Platelet Count
Time Factors
Treatment Outcome

Substances

Anticoagulants
Enoxaparin